LGALS3 and metabolic syndrome: The Gal-3 presentation has been documented in a variety of cardiac and noncardiac conditions in companies with AF, such as coronary artery and other heart diseases, metabolic syndrome, diabetes, chronic renal failure, as well as ischemic stroke.